(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 15.18% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.1%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Amphastar Pharmaceuticals's revenue in 2024 is $644,395,000.On average, 4 Wall Street analysts forecast AMPH's revenue for 2024 to be $36,716,958,201, with the lowest AMPH revenue forecast at $35,639,033,742, and the highest AMPH revenue forecast at $38,273,725,062. On average, 3 Wall Street analysts forecast AMPH's revenue for 2025 to be $41,835,367,931, with the lowest AMPH revenue forecast at $40,821,843,831, and the highest AMPH revenue forecast at $42,845,717,704.
In 2026, AMPH is forecast to generate $47,436,948,691 in revenue, with the lowest revenue forecast at $44,186,149,378 and the highest revenue forecast at $51,746,337,926.